Imperial Announces New Family of Companies Including Exclusive Life-Science Translation Provider
PHILADELPHIA (June 25, 2012)--The life-science industry's largest tradeshow, the 48th Annual DIA, is the backdrop for today's debut of the new "Imperial Family of Companies" comprising DAC Patient Recruitment Services, Imperial Graphics and ClinicaLingua Translation Services--three vertically integrated brands which provide Pharma/Biotech/Devices with true service synergy. Executives of Imperial, a 40-year veteran in the clinical research space, tout the new family model for its ability to help clients save time, maximize resources and minimize risk by offering the strength of three companies, with the simplicity and convenience of one point of contact.
Of particular note, the addition of ClinicaLingua fills a void for clients challenged with ensuring accurate and appropriate translations for physician and patient audiences, coordinating communication and file management on a global scale, while managing complexities in the translation of all study and recruitment materials.
"Both announcements are pivotal to our organization," said Matthew Bissell, CEO of Imperial. "We have undergone a lot of positive change and growth that needs to be communicated to our clients and the industry as a whole. The 'Family of Companies' model with common ownership and management helps us position that message."
ClinicaLingua's infrastructure and team complement Imperial's already growing translation services segment. "Our skillset, clinical focus and ISO-certified standards tie-in well to the strategic vision of the Imperial organization," stated Scott Van Til, manager at ClinicaLingua.
DAC Patient Recruitment Services (formerly D. Anderson & Company) offers strategic site selection, country-customized patient recruitment and retention, award-winning creative services, and CEU-certified global clinical staff training. A trusted brand in the life-sciences industry for over four decades, Imperial Graphics provides high-end design and printing of site materials, custom kit production, fulfillment, global logistics, and electronic site closure services.
On location at DIA this week, Steve Swanson, president and COO of Imperial, said: "Imperial is a highly specialized functional service provider (FSP). Historical FSP models rely on an aggregated group of suppliers that forces project managers to expend unnecessary effort and time to deal with different vendors and dissimilar business systems. The ownership versus partnership found within our model offers compatible business systems, consolidated contracts, and the model-wide goal congruence necessary to drive tangible efficiencies. We are one of the few, if not the only firm, in the clinical trial space with this type of specialized integration. Our businesses are 100 percent focused on the clinical space, unlike others where it is only one of their business segments."
Since its founding in 1945, Imperial has become one of the world's premier support organizations for sponsors and CROs. As Bissell concluded, "We have been in this business longer than most, and have seen significant transitions take place. Throughout these transitions, Imperial has remained committed to innovation and change in order to exceed our customers' needs and expectations. Today's announcements reinforce that commitment."
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.